Submit Deal

GENMAB AS

HQ - Copenhagen

Summary

Genmab is a biotechnology company that focuses on the development and commercialization of differentiated antibody therapeutics for the treatment of cancer.

Deals Overview

Total Deals2

Valued Deals2

Total Value£ 7.33 B

Avg. Deal Size£ 3.67 B

Market Context

Senior Management

Jan van de Wilken
President and CEO
Jan van de Winkel
President and CEO
Andrew Carlsen
Vice President

Sort

03 Apr 2024|United States|Biotechnology

Target: PROFOUNDBIO

Bidder: GENMAB AS

13 Service Providers

7 Target | 6 Bidder

91 Dealmakers

56 Target | 35 Bidder

£ 1.43 B

Value

29 Sep 2025|Netherlands|Biotechnology

Target: MERUS B.V.

Bidder: GENMAB AS

10 Service Providers

5 Target | 5 Bidder

55 Dealmakers

45 Target | 10 Bidder

£ 5.90 B

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy